- ONCO Prime is a cutting-edge drug discovery platform
identifying novel synthetic lethal targets using patient-derived
primary cell cultures. Initial data have identified potentially
novel drug targets in KRAS-mutant colorectal cancer (CRC), and the
platform has broad applicability across multiple tumor
types.
- Krzysztof Brzózka, Ryvu's Chief Scientific Officer and
Executive Vice President, will present the ONCO Prime platform
during the 6th Annual RAS-Targeted Drug Development Summit on
September 25 at 4:45 PM (ET, Boston).
KRAKOW, Poland, Sept. 23,
2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a
clinical-stage drug discovery and development company focusing
on novel small molecule therapies that address emerging targets
in oncology, will present its ONCO Prime drug discovery
platform at the 6th Annual RAS-Targeted Drug Development Summit, a
leading global end-to-end RAS therapies forum, which will take
place on September 24-26 in
Boston, MA.
ONCO Prime is a cutting-edge drug discovery platform identifying
novel synthetic lethal targets using patient-derived primary cell
cultures. The platform comprises of new cancer models with the
optimal ratio of translational potential and high-throughput
feasibility. By using patient-derived cells, the ONCO Prime
platform uses patients' medical history combined with
histopathological, genomic, and transcriptomic data to enable the
correlation of clinical and molecular data. Initial platform
screens have identified potentially novel drug targets in
KRAS-mutant colorectal cancer (CRC). Additionally, the platform has
broad applicability across multiple tumor types, and additional
screens in other major tumor areas are ongoing.
Krzysztof Brzózka, Ph.D., Chief Scientific Officer and
Executive Vice President of Ryvu Therapeutics, said:
- "We are proud that, within a short time since its
development began in mid-2023, the ONCO Prime platform has already
identified novel targets in KRAS-mutant cells – targets overlooked
by conventional immortalized CRC cell lines. This achievement
highlights the platform's unique capability, and we're excited to
discuss its implications with the international RAS-focused
community."
ONCO Prime is co-financed by the European Union under the
Operational Programme European Funds for Modern Economy 2021-2027.
Project title: "ONCO Prime: new possibilities for personalised
anti-cancer therapy based on patient-derived primary cell cultures,
omics characterisation, and functional assays". Grant Agreement no:
FENG.01.01-IP.02-0095/23. This co-financing is being administered
through the Polish Agency for Enterprise Development (PARP). Ryvu
expects to receive PLN 26.3 million (approximately USD 6.6 million) in grant funding over five years
to support ONCO Prime.
The 6th Annual RAS-Targeted Drug Development Summit is the
central hub dedicated to every aspect of RAS discovery and
development, from discovery and clinical development to
commercialization. It equips 150+ global RAS leaders with the means
to create effective RAS therapies for better patient outcomes.
More details: ras-drugdevelopment.com
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical-stage drug discovery and
development company focused on novel small-molecule therapies that
address emerging targets in oncology. Internally discovered
pipeline candidates at Ryvu use diverse therapeutic mechanisms
driven by emerging knowledge of cancer biology, including small
molecules directed at kinases, synthetic lethality, and
immuno-oncology targets.
Ryvu's most advanced program is RVU120, a selective CDK8/CDK19
kinase inhibitor with the potential to treat hematological
malignancies and solid tumors. RVU120 is currently in Phase II
development (i) as a monotherapy for the treatment
of patients with relapsed/refractory acute myeloid leukemia
(r/r AML) and high-risk myelodysplastic syndromes (HR-MDS) – the
RIVER-52 study, (ii) in combination with venetoclax for the
treatment of patients with r/r AML – the RIVER-81 study, and
(iii) as a monotherapy for the treatment of patients with lower
risk myelodysplastic syndromes (LR-MDS) – the REMARK study.
SEL24 (MEN1703) is a dual PIM/FLT3 kinase inhibitor licensed to the
Menarini Group that is expected to start a Phase II study in
diffuse large B-cell lymphoma (DLBCL) in Q4 2024. RVU305, a
potentially best-in-class PRMT5 inhibitor aiming to treat multiple
solid tumors, is currently undergoing IND/CTA-enabling studies.
Ryvu Therapeutics has signed 11 partnering and licensing deals with
global companies, including BioNTech and Exelixis.
The company was founded in 2007 and is headquartered in Kraków,
Poland. Ryvu is listed on the
Warsaw Stock Exchange and is a component of the mWIG40 index. For
more information, please see www.ryvu.com.
View original
content:https://www.prnewswire.com/news-releases/ryvu-therapeutics-to-present-onco-prime-platform-at-the-6th-annual-ras-targeted-drug-development-summit-302255701.html
SOURCE Ryvu Therapeutics